Comparative analysis of six European influenza vaccines

被引:43
作者
Chaloupka, I
Schuler, A
Marschall, M
MeierEwert, H
机构
[1] Abteilung für Virologie, Inst. F. Medizinische Mikrobiologie, TU München, 80802 Munich
关键词
D O I
10.1007/BF01591484
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Three split-virion vaccines (Vaxigrip, Begrivac, and Influsplit/Fluarix) and three subunit vaccines containing only viral surface glycoproteins (Influvac, Agrippal, and Fluvirin) available for the 1994-95 season were analysed by biological, molecular, and biochemical methods. Although all vaccines are required by health authorities to contain 15 mu g haemagglutinin per dose of each virus strain, there were significant differences in haemagglutination titres among the examined vaccines of both types. The enzymatic activity of neuraminidase was present in all vaccines except Fluvirin. Total protein content was lower for subunit vaccines. Viral nucleoprotein was detected in all split vaccines but to varying levels according to SDS-PAGE and Western blot analyses. The ovalbumin content was low in general but was about tenfold higher for Influvac than for the other vaccines analysed. This protein may induce hypersensitive reactions among persons with severe egg allergy. All three split-virion vaccines were found to contain the matrix protein; however, it was not detected in the subunit vaccines. Differences in influenza antigen variety in currently available vaccines may affect efficacy, whereas differences in concentrations of nonviral compounds such as ovalbumin and endotoxin may lead to different postvaccination reactogenicity profiles.
引用
收藏
页码:121 / 127
页数:7
相关论文
共 13 条
[1]   RECOMMENDATIONS OF THE 7TH EUROPEAN MEETING OF INFLUENZA AND ITS PREVENTION [J].
AYMARD, M ;
COX, NJ ;
DUBOIS, G ;
GHENDON, Y ;
HANNOUN, C ;
HAMPSON, A ;
HAAHEIM, LR ;
MORGANCAPNER, P ;
SALIOU, P ;
TAMBLYN, S .
EUROPEAN JOURNAL OF EPIDEMIOLOGY, 1994, 10 (04) :525-526
[2]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[3]  
*EUR PHARM SPEC PR, 1994, VACC INFL IN CORT AN, P1
[4]  
GORSE JG, 1995, J INFECT DIS, V172, P1
[5]   THE B-CELL RESPONSE IN LYMPHOID-TISSUE OF MICE IMMUNIZED WITH VARIOUS ANTIGENIC FORMS OF THE INFLUENZA-VIRUS HEMAGGLUTININ [J].
JUSTEWICZ, DM ;
DOHERTY, PC ;
WEBSTER, RG .
JOURNAL OF VIROLOGY, 1995, 69 (09) :5414-5421
[6]   MEASUREMENT OF ANTIINFLUENZA NEURAMINIDASE ANTIBODY USING A PEROXIDASE-LINKED LECTIN AND MICROTITRE PLATES COATED WITH NATURAL SUBSTRATES [J].
LAMBRE, CR ;
TERZIDIS, H ;
GREFFARD, A ;
WEBSTER, RG .
JOURNAL OF IMMUNOLOGICAL METHODS, 1990, 135 (1-2) :49-57
[7]  
PALMER DF, 1975, IMMUNOLOGY SERIES, V6, P34
[8]   MORPHOLOGICAL AND BIOCHEMICAL-CHARACTERIZATION OF INFLUENZA VACCINES COMMERCIALLY AVAILABLE IN THE UNITED-KINGDOM [J].
RENFREY, S ;
WATTS, A .
VACCINE, 1994, 12 (08) :747-752
[9]   LICENSING AND CONTROL AUTHORITY BATCH RELEASE OF INFLUENZA VACCINE IN GERMANY IN ACCORDANCE WITH EEC REGULATIONS [J].
WEEKELUTTMANN, M .
EUROPEAN JOURNAL OF EPIDEMIOLOGY, 1994, 10 (04) :513-514
[10]   INFLUENZA - DIAGNOSIS, MANAGEMENT, AND PROPHYLAXIS [J].
WISELKA, M .
BRITISH MEDICAL JOURNAL, 1994, 308 (6940) :1341-1345